Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The dysfunction of natural killer (NK) cells has been increasingly reported in malignancies, especially in solid tumours. Mesenchymal stem cells (MSCs) exhibit pleiotropic functions that include mediating immune cell exhaustion which is implicated in cancer progression. However, the association of MSCs derived from gastric cancer (gastric cancer mesenchymal stem cells: GCMSCs) with the dysfunction of NK cells remains poorly understood. In this study, we demonstrated that GCMSCs effectively contributed to the exhaustion of NK cells through the release of soluble factors. Furthermore, passivation of the antitumour effect in NK cells was closely associated with their dysfunctional state. The GCMSC-conditioned medium prevented the frequency and effector function of infiltrating NK cells in tumour-bearing mouse models, thus promoting tumour growth. Mechanistically, mammalian target of rapamycin (mTOR) signalling, a critical regulator of cellular metabolism that mediates the function of immune cells, was inhibited in NK cells treated with GCMSCs. However, the checkpoint receptor PD-1 was still present at minimal levels with or without GCMSCs. The study results revealed that GCMSCs contributed to dysfunctional NK cells involved at least partially in the inhibition of mTOR signalling, suggesting potential directions for NK cell-based cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614 · cited 1×
“Despite major advances in surgical procedures and other therapies, the overall 5-year survival rate for GC remains less than 30% in most countries [2].”
BackgroundImmunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140 · cited 1×
“As a critical component in the TME, MSCs can effectively promote the initiation and promotion of many types of tumours [34].”
BackgroundContribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817 · cited 2×
“Immunotherapy targeting the PD1/PD-L1 inhibitory axis elicited long-term remission in a broad spectrum of cancers [11].”
BackgroundNi, J., Wang, X., Stojanovic, A., Zhang, Q., Wincher, M., Bühler, L., Arnold, A., Correia, M. P., Winkler, M., Koch, P.-S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.001 · Cited by 324
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145 · cited 1×
“Many tumour types exhibit a high incidence of major histocompatibility complex (MHC) loss or low neoantigen burden [6], rendering tumour cells refractory to recognition by CD8 T cells.”
Background
Cited by
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity
Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212429 · Cited by 67
“The cross-talk between CA-MSCs and NK cells is crucially important for the optimal MSC-driven suppression of anti-tumor immunity [20].”
BackgroundSlama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
“174,175 The role of extracellular vesicles (EVs) derived from MSCs (MSCs-EVs) in cancer cell proliferation has been extensively explored and validated.”
Background
Metadata
- Authors
- Guo, S., Huang, C., Han, F., Chen, B., Ding, Y., Zhao, Y., Chen, Z., Wen, S., Wang, M., Shen, B., & Zhu, W.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2021-06-29
- Volume
- 2021
- Pages
- 1-17
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W3173782511
- Cited by
- 28
- References
- 5
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth. https://app.cochat.ai/papers/10.1155/2021/9989790
- The paper
- Guo, S., Huang, C., Han, F., Chen, B., Ding, Y., Zhao, Y., Chen, Z., Wen, S., Wang, M., Shen, B., & Zhu, W. (2021). Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth. Stem Cells International. https://doi.org/10.1155/2021/9989790
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.